A study using a diet-induced obesity model with or without TPL2 knockout demonstrated that TPL2 deletion reduces peripheral inflammation and hepatic steatosis, and improves whole-body insulin resistance in obese mice, mimicking MHO observed in humans [68]. This evidence concerns the gene MAP3K8 and fatty liver disease.